Is there a role for soluble guanylate cyclase stimulators in acute pulmonary embolism?

Critical Care Medicine

Volumn 39, Issue 12, 2011, Pages 2773-2774

  Appavu, Samuel K ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

nitric oxide; nitrite oxide syntheses; pulmonary embolism; pulmonary vasoconstriction; RV dysfunction; soluble guanylate cyclase stimulators

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; GUANYLATE CYCLASE ACTIVATOR; LACTIC ACID;

ARTERIAL BLOOD; DOSE RESPONSE; EDITORIAL; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE PRESSURE; HYPOXEMIA; LACTIC ACID BACTERIUM; LOW DRUG DOSE; LUNG EMBOLISM; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANIMALS; GUANYLATE CYCLASE; MALE; MORPHOLINES; PULMONARY EMBOLISM; PYRIMIDINES; VASODILATOR AGENTS;

EID: 81855185921     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822b3a34     Document Type: Editorial

References (12)

1. McIntyre KM, Sasahara AA: Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974; 65:534-543
2. The UKEP study research group: Multicentre clinical trial on two local regiments of urokinase in massive pulmonary embolism: The UKEP study. Eur Heart J 1987; 8:2-10
3. Szold O, Khoury W, Biderman P, et al: Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: A report of four cases and review of the literature. Lung 2006; 184:1-5
4. Atz AM, Adatia I, Wessel DL: Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62: 1759-1764 (Pubitemid 26421112)
5. Dellinger RP, Zimmerman JL, Taylor RW, et al: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial. Crit Care Med 1998; 26:15-23 (Pubitemid 28028435)
6. Oishi P, Grobe A, Benavidez E, et al: Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: A role for superoxide and peroxynitrite in the intact lamb. Am J Physiol Lung Cell Mol Physiol 2005; 290:L359-L366
7. Hoenicka M, Schmid C: Cardiovascular effects of modulators of soluble guanylyl cyclase activity. Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6:287-301
8. Gur S, Kadowitz PJ, Hellstrom WJ: Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Res (Netherlands) 2010; 16:1619-1633
9. Stasch JP, Alonso-Alija C, Apeler H, et al: Pharmacological actions of a novel NOindependent guanylyl cyclase stimulator: in vitro studies. Br J Pharmacol 2002; 135: 333-343 (Pubitemid 34151165)
10. Watts JA, Gellar MA, Fulkerson MK, et al: Pulmonary vascular reserve during experimental pulmonary embolism: Effects of a soluble guanylate cyclase stimulator, BAY 41-8543. Crit Care Med 2011; 39: 2700-2704
11. Smulders YM: Pathophysiology and treatment of hemodynamic instability in acute pulmonary embolism: The pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48:23-33
12. Cau SB, Dias-Junior CA, Montenegro MF, et al: Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur J Pharmacol 2008; 581:132-137